If you have been reading about thymosin alpha-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-25. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of lymphocyte-derived cutaneous lymphoma and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma, and agranular CD4+ NK cell leukemia. Later, however, the disease was determined to be a malignancy of plasmacytoid dendritic cells rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the World Health Organization designated BPDCN to be in its own separate category within the myeloid class of neoplasms. It is estimated that BPDCN onstitutes 0.44% of all hematological malignancies. Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy with features of cutaneous lymphoma (e.g. malignant plasmacytoid dendritic cell infiltrations into the skin to form single or multiple lesions) and/or leukemia (i.e. malignant plasmacytoid dendritic cells in blood and bone marrow). While commonly presenting with these clinical features, BPDCN, particularly in its more advanced stages, may also involve malignant plasmacytoid dendritic cell infiltrations in and thereby injury to the liver, spleen, lymph nodes, central nervous system, or other tissues. The neoplasm occurs in individuals of all ages but predominates in the elderly; in children, it afflicts males and females equally but in adults is far more common (~75% of cases) in males. Blastic plasmacytoid dendritic cell neoplasm typically responds to chemotherapy regimens used to treat hematological malignancies.
Instant coffee is a beverage derived from processed brewed coffee beans that is quickly prepared by adding hot water or milk to powdered solid coffee extracts. Instant coffee solids in powdered or crystallized form (also called soluble coffee, coffee extract, coffee crystals, coffee powder, or powdered coffee, and often sold as "instant coffee") refers to dehydrated and packaged solids used to make the instant coffee beverage. The product was invented in 1890 in Invercargill, Southland, New Zealand by David Strang. Instant coffee solids are commercially prepared by either freeze-drying or spray drying coffee beverage. Instant coffee is also manufactured in a concentrated liquid form. Instant coffee has advantages over coffee brewed from ground coffee beans including speed of preparation (instant coffee dissolves quickly in hot water), lower shipping weight and volume than beans or ground coffee for the same amount of beverage, and long shelf life—though instant coffee can spoil if not kept dry. However, the beverage made from ground coffee is considered to have superior quality and taste. Instant coffee also reduces cleanup since there are no coffee grounds. At least one study has found that instant coffee has a lower environmental footprint than drip filter coffee and capsule espresso coffee, on a prepared beverage basis, disregarding quality and appeal of the beverage produced. The global instant coffee market was valued at US$4.16 Billion in 2026.
=== Final Cuban offensive === Although the SADF and UNITA counteroffensive had been checked, FAPLA remained heavily strained and more dependent than before on its Cuban allies and Soviet materiel. This gave dos Santos an incentive to ease the military dilemma with negotiations and he reopened the possibility of reaching a new ceasefire and disengagement agreement with South Africa. As early as January 1987, Chester Crocker had responded to positive signals from Luanda, especially when President Denis Sassou Nguesso of the People's Republic of the Congo offered to mediate peace talks between the rival states. Yet preliminary discussions in Brazzaville throughout late 1987 and early 1988 remained stymied by the Angolan government's refusal to compromise on the timetable for a proposed Cuban withdrawal. The Cuban government had not been consulted on the Brazzaville talks in advance and resented what it perceived as a discourtesy on the part of dos Santos. This factor had the effect of persuading Castro to make an authoritative bid to join the Angolan-US peace talks. He was determined that Cuba no longer be excluded from negotiations concerning its own military, and the results of any future settlement on the withdrawal process leave Cuba's image untarnished.
=== Brick Structure Synthesis === A canonical DNA brick is a “32-nucleotide single strand with four 8-base binding domains (sticky ends)”. While each DNA brick has a distinct nucleotide sequence, they are all able to adopt the brick structure consisting of two 16-nucleotide antiparallel helixes joined by a single phosphate linkage. The two domains attached to the phosphate linkage are designated as “head” and “tail” domains. To bind two DNA bricks, a “head” domain will bind to a neighboring brick if their “tail” domain is the complementary strand of the earlier, and vice versa, producing a 90° dihedral angle. The concept of a Lego-like model is meant to depict the design in a simpler manner. Looking at a singular model in this manner, the two protruding round holes represent the two “tail” domains while recessed round holes represent the two “head” domains. Also, the brick can adopt a horizontal or vertical orientation. Using 3D modeling software such as LegoGen and Cadnano, it is possible to design DNA bricks by simply defining the target shape and subsequently the computer program can analyze it and automatically select the correct subset of bricks for self-assembly of the shape without having to manually design every DNA interaction.
Although most applications focus on the detection of positive ions, measurements in the negative mode are for most of the plasma-based ion sources also possible. In this case, reagent ions, such as O2–, can deprotonate the analyte molecules to give [M–H]– quasimolecular ions, or form adducts with species such as NO3–, yielding [M+NO3]– ions. Measurements in the negative ion mode are especially favorable when the analyte molecules exhibit a high gas-phase acidity, as is the case for carboxylic acids. One of the most used plasma-based techniques for ambient ionization is probably direct analysis in real time (DART), since it is commercially available. DART is an atmospheric pressure ion source that operates by exposing the sample to a gas stream (typically helium or nitrogen) that contains long-lived electronically or excited neutral atoms, vibronically excited molecules (or "metastables"). Excited states are formed in a glow discharge in a chamber through which the gas flows.
Sources: en.wikipedia.org
March 13 The Trump administration announces an expanded trade probe and investigations into Canada and 60 other countries. NBC News reports that an additional 5,000 U.S. troops along with more warships are to be deployed to the Middle East, following a request by CENTCOM. March 14 – Trump announces that U.S. forces have "totally obliterated" all military targets on Kharg Island, which handles the vast majority of Iran's oil exports. March 15 – The 98th Academy Awards are held at the Dolby Theatre in Los Angeles, honoring the best films released in 2025. One Battle After Another wins the Academy Award for Best Picture. March 16 A federal judge blocks the CDC's Advisory Committee on Immunization Practices changes to vaccine policy, including revisions to the childhood immunization schedule. The judge rules that the policy changes were arbitrary and capricious and that HHS Secretary Kennedy illegally fired and replaced committee members. Trump urges allied countries to assist in securing and reopening the Strait of Hormuz following its effective closure by Iran. March 17 Joe Kent resigns as director of the National Counterterrorism Center, citing disagreement over American involvement in the Iran war. Trump criticizes NATO and other U.S. allies, saying he's been told they "don't want to get involved" in the Iran war. Arizona Attorney General Kris Mayes files the first criminal charges against Kalshi, alleging that the prediction market is hosting illegal gambling and breaking state law by betting on elections.
In the US, Aducanumab is indicated for the treatment of Alzheimer's disease. In July 2021, the US Food and Drug Administration (FDA) limited the indication to people with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Aducanumab is a monoclonal IgG1 antibody that binds to the amyloid beta protein at amino acids 3–7, which is posited to result in slowing the progression of Alzheimer's disease. The mechanism is based on the amyloid hypothesis, which posits that amyloid proteins cause Alzheimer's disease, hence removing amyloid should slow the progression of the disease. How the antibody accesses the plaques is under active research. One mechanism suggests the plaques are exposed to the lumen of blood vessels and the antibody accesses the plaques from the lumen side. This assumes the plaque formed as a result of a leaky blood brain barrier and may also explain why there is hemorrhage after the plaques are removed. The most common serious adverse reactions reported are:
In May 1952, Raymond Gosling, a graduate student working under the supervision of Rosalind Franklin, took an X-ray diffraction image, labeled as "Photo 51", at high hydration levels of DNA. This photo was given to Watson and Crick by Maurice Wilkins and was critical to their obtaining the correct structure of DNA. Franklin told Crick and Watson that the backbones had to be on the outside. Before then, Linus Pauling, and Watson and Crick, had erroneous models with the chains inside and the bases pointing outwards. Franklin's identification of the space group for DNA crystals proved her correct. In February 1953, Linus Pauling and Robert Corey proposed a model for nucleic acids containing three intertwined chains, with the phosphates near the axis, and the bases on the outside. Watson and Crick completed their model, which is now accepted as the first correct model of the double helix of DNA. On 28 February 1953 Crick interrupted patrons' lunchtime at The Eagle pub in Cambridge, England to announce that he and Watson had "discovered the secret of life".
Nucleic acid (DNA and RNA) strands with corresponding sequences stick together in pairwise chains. But each node of the chain is not very sticky, so the double-stranded chain is continuously coming partway unzipped and re-zipping itself under the influence of ambient vibrations (referred to as thermal noise or Brownian motion). Longer pairings are more stable. Nucleic acid tests use a "probe" which is a long strand with a short strand stuck to it. The long primer strand has a corresponding (complementary) sequence to a "target" strand from the disease organism being detected. The disease strand sticks tightly to the exposed part of the long primer strand (called the "toehold"), and then little by little, displaces the short "protector" strand from the probe. In the end, the short protector strand is not bound to anything, and the unbound short primer is detectable. The rest of this section gives some history of the research needed to fine-tune this process into a useful test.
Sources: en.wikipedia.org
Bromocriptine, sold under the brand name Parlodel among others, is an ergoline derivative and dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome, and, as an adjunct, type 2 diabetes. It was patented in 1968 and approved for medical use in 1975.
Thaçi was designated as the next leader of Kosovo's government on 11 December 2007 by the Kosovar president Fatmir Sejdiu and told to form a government "as soon as possible". His Democratic Party of Kosovo (PDK) began coalition talks with the Democratic League of Kosovo (LDK) as well as the Alliance for New Kosovo (AKR). Those parties cumulatively controlled 75 of the assembly's 120 seats. On 9 January 2008, Thaçi was elected prime minister by parliament, with 85 votes in favor and 22 against. On this occasion, he stated his intention to achieve independence for Kosovo in the first half of 2008. On 16 February 2008, Thaçi announced that the next day would be key for "implementing the will of the citizens of Kosovo", strongly implying the province would declare independence from Serbia. On 17 February, Kosovo declared its independence from Serbia. Thaçi became prime minister of the newly independent state. On 6 June 2008, a gunman broke into Thaçi's home in Pristina. Thaçi was not in his home when the break-in occurred.
== Transport == Charlotte Douglas International Airport, North Carolina, US (IATA:CLT) Cilebut railway station, Indonesia Clacton-on-Sea railway station, Clacton on Sea, UK Kozhikode railway station, Kerala, India
, respectively. Michaelis–Menten kinetics relies on the law of mass action, which is derived from the assumptions of free diffusion and thermodynamically driven random collision. Many biochemical or cellular processes deviate significantly from these conditions, because of macromolecular crowding and constrained molecular movement. More recent, complex extensions of the model attempt to correct for these effects.
=== Anatomical features === The vitreous has many anatomical landmarks, including the hyaloid membrane, Berger's space, space of Erggelet, Wieger's ligament, Cloquet's canal and the space of Martegiani. Surface features:
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.